There is an unmet need for effective pharmacological therapies for constipation, a symptom that significantly deteriorates patients' quality of life and impacts health care. Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor and has been shown to exert prokinetic effects on gastrointestinal (GI) motility via the vagus and pelvic nerves. The pharmacological potential of ghrelin is hampered by its short half-life. Ghrelin receptor (GRLN-R) agonists with enhanced pharmacokinetics were thus developed. Centrally penetrant GRLN-R agonists stimulate defecation and improve impaired lower GI transit in animals and humans. This review summarizes the current knowledge on relamorelin, a potent ghrelin mimetic, and other GRLN-R analogs which are in preclinical or clinical stages of development for the management of disorders with underlying GI hypomotility, like constipation. 
Introduction
Constipation as a chronic digestive condition significantly deteriorates patients' quality of life. It is much more common amongst women compared to men and the probability of the occurrence of constipation increases with age. The worldwide prevalence rates of physician-confirmed or patient self-reported constipation ranges from 12.3% to 25.1%. [1] [2] [3] [4] [5] In clinical practice the separation between chronic idiopathic constipation (chronic constipation [CC] of undefined pathophysiology that does not have any organic or physiological cause), constipation-predominant irritable bowel syndrome (IBS-C), and CC (gastrointestinal [GI] disorder caused by normal colon transit, slow colon transit or dyssynergic defecation) is still difficult. 6 Although the diagnosis of IBS-C is based on the Rome IV criteria, the diagnosis of CC is made by exclusion of other conditions without thorough investigation. The Bristol stool scale serves as an universal tool for the determination of stool consistency. Regardless of the final diagnosis, each condition is characterized by feeble or absent colonic propagated activity. A great number of drugs tested in preclinical in vivo studies for the treatment of IBS-C are simultaneously verified also as a potential option for CC or chronic idiopathic constipation. Currently, conventional treatment options used to improve constipation-related symptoms like ab- 7, 8 Ghrelin is a 28-amino acid peptide produced mainly in the P/ D1 and X/A-like cells of the oxyntic mucosa of the stomach and in the hypothalamus. Importantly, the X/A-like endocrine cells are solely responsible for 80-90% secretion of ghrelin. The peptide has recently been described as a natural ligand for the ghrelin receptor (GRLN-R), also known as the growth hormone secretagogue-1α receptor. GRLN-Rs are expressed in the central nervous system and in peripheral tissues and are involved in numerous functions [9] [10] [11] [12] [13] [14] [15] [16] [17] ; the main central and peripheral functions are summarized in Figure. The activation of GRLN-R modulates multiple intracellular signaling pathways and exhibits different endocrine and non-endocrine effects. 18 While administered either peripherally or centrally, ghrelin stimulates food intake through GRLN-Rs on vagal afferents or via the bloodstream. 15, 19 Moreover, by targeting hypothalamic neurons and the sympathetic nervous system, ghrelin regulates lipid-metabolizing enzymes in adipocytes. 20 Ghrelin also interacts with the reproductive, cardiovascular and immune systems. [21] [22] [23] [24] [25] Currently, ghrelin is considered as a possible option for the treatment of conditions with impaired gastric motility, reduced GI motility and altered energy balance.
Since the discovery of ghrelin in 1999, 26 its usefulness was thoroughly evaluated in the treatment of upper GI diseases, especially gastroparesis. More recent studies in animals and humans report a prokinetic activity in the lower GI-tract with ghrelin potentially being helpful for the treatment of lower GI diseases, such as CC or postoperative ileus (POI). 27, 28 Although the expression of ghrelin is relatively low in the small and large intestines, when compared to the stomach, the GRLN-Rs are in turn dispersed throughout the GI tract and a high mRNA expression was reported especially in the colon of humans and rodents. In more detail this high expression was reported on fibers and cell bodies of the enteric nervous system in rats, and in the myenteric neurons of the guinea pig ileum. 20, 29, 30 Numerous studies in rodents demonstrate an enhanced motor activity in the duodenum following administration of exogenous ghrelin in the fed or fasted state. [31] [32] [33] Moreover, the activation of GRLN-Rs by centrally penetrant GRLN-R agonists in the lumbosacral spinal cord initiates and enhances propulsive contractile activity in the distal colon. 33, 34 Ghrelin induces contractile activity in the GI tract, but the short half-life and plasma instability of ghrelin impairs the usefulness. 35 Hence, small molecule-GRLN-R agonists with prolonged receptor activity currently represent an attractive therapeutic option for the management of lower GI tract motility disorders. In this review we summarize the latest preclinical and clinical studies evaluating the potential of relamorelin and other GRLN-R agonists in improving delayed colonic transit.
Relamorelin
Relamorelin (RM-131) is a pentapeptide synthetic ghrelin analog that stimulates the release of growth hormone in a comparable manner as natural ghrelin. It binds to the GRLN-R with approximately 3-fold higher affinity to ghrelin receptors than native ghrelin. 36, 37 Moreover, RM-131 exerts improved stability, greater potency, and longer plasma half-life. 36, 38 RM-131 may be used in the treatment of gastroparesis, since in gastroparesis RM-131 accelerates gastric emptying without causing severe adverse effects.
The most common side effects in RM-131 treated patients are dizziness, fatigue, abdominal pain/cramping, hunger, feeling cold, and muscular weakness. 39 Considering the prokinetic properties of RM-131 on the upper GI tract, many studies put also an interest on its effect in the treatment of the lower GI motility disorders. A study by Van der Ploeg et al 36 showed that RM-131 reversed the reduction of gastric emptying and was up to 100-fold more potent than ghrelin or other ghrelin mimetics in rat models of POI and morphine-induced ileus. Besides its effect on gastric emptying, oral administration of RM-131 also enhanced GI transit in the proximal and middle part of the small intestine. Moreover, in a rat model of TNBS-induced GI inflammation the administration of a single dose of RM-131 (5 or 50 nmol/mouse) increased the rats' survival and reduced signs of macroscopic colonic inflammation, suggesting that RM-131 also mediates an anti-inflammatory response. 36 Translated into humans, in a randomized, double-blinded, placebo-controlled trial, RM-131 administered subcutaneously for 14 days at the dose of 100 µg/day significantly reduced the symptoms of constipation in females with CC who met the Rome III criteria. 37 RM-131 significantly enhanced bowel function by increasing the number of spontaneous bowel movements and accelerated GI and colonic transit. Importantly, the positive response was observed immediately after the first administration of RM-131. The primary clinical endpoint for the function of the intestine was stool consistency (assessment based on the Bristol stool scale), and the secondary endpoints included stool frequency, time to first bowel movement and completeness of evacuation. The ghrelin agonist was welltolerated. Some patients experienced tiredness, enhanced appetite and headache.
More recently, Acosta et al 40 characterized the acute motor effects of RM-131 in patients with CC using colonic barostat and multilumen manometry. In a placebo-controlled, single dose, double blind, randomized study Acosta et al 41 showed that a subcutaneous injection of isotonic RM-131 solution significantly increased colonic propagated contractions (PCs) and in consequence accelerated overall colonic motor activity. No differences in the number of high amplitude propagated contractions (HAPCs) and in sensation thresholds for gas and pain were observed between the RM-131-treated and control groups. However, the administration of RM-131 resulted in an increased frequency of pre-meal PCs and a significantly higher number of postprandial PCs, when compared to the placebo group. The observed activity in the colon is comparable to the effects seen following a treatment with other colonic prokinetics such as prucalopride, or other serotonin receptor agonists or neostigmine; however, in contrast to the above mentioned drugs RM-131 exhibits a delayed effect (24-36 hour postadministration) on the colonic motility. [42] [43] [44] To further characterize the effects reported in the human colon the same group of authors evaluated the clinical efficacy of RM-131 in patients with confirmed CC. Similarly to their first clinical trial, the propulsive effects of RM-131 were confirmed, and the trial added that the duration of RM-131 is long-lasting with RM-131 activity being reported for a minimum of 1 hour. 41 Another study interested in the underlying mechanisms demonstrated that RM-131 hyperpolarizes the resting membrane potential of mouse and human colon circular smooth muscle cells and decreases colonic intraluminal pressure. 45 RM-131 exerted no effect on either fast inhibitory junction potentials or slow inhibitory junction potentials. The concurrent effect of RM-131 in decreasing colonic intraluminal pressure and increasing upper GI contractility may widen its application towards functional GI disorders. 46 Very recently, a single-center, placebo-controlled, double-blinded study was initiated in patients with CC who received a single injection of 100 µg of RM-131. The primary endpoint included the effect of RM-131 on postprandial HAPC within one hour. No results have been published yet; however, the trial may be followed under the Clinical Trial registration number (ClinicalTrals gov. Identifier: NCT 02137642).
Other Ghrelin Receptor Agonists
The defecation center in the lumbo-sacral spinal cord constitutes an investigational target for the treatment of constipation. Small-molecules, such as urimorelin, capromorelin, EX-1314, CP464709, GSK894281, and ipamorelin stimulate this center and are thought to ameliorate bowel movement in animals. A small number of clinical trials have been performed so far (Table 1) .
Ulimorelin (TZP-101)
Ulimorelin is a macrocyclic peptidomimetic agent widely investigated in the management of diabetic gastroparesis (ClinicalTrials. gov Identifier: NCT00612014) and POI (ClinicalTrials.gov Identifier: NCT01710982) but more recently it is also in the spotlight in the treatment of constipation. Pustovit et al 47 reported a dose-dependent increase in the numbers and amplitudes of phasic pressure waves in the colorectum in anesthetized rats following intravenous administration of ulimorelin. Interestingly, when delivered directly to the lumbo-sacral spinal cord, ulimorelin increased propulsive activity more significantly compared to intravenous injections. The effect of ulimorelin was blocked by both the nicotinic receptor antagonist (hexamethonium) and GRLN-R antagonist, indicating that the responses were dependent on sustained activation of neuronal pathways. Yet, there are no clinical trials evaluating the effect of this GRLN-R agonist in patients with constipation.
Capromorelin
In a rat model of low fiber-induced constipation, capromorelin stimulates colonic motility and improves defecation patterns. 48 Ferens et al 34 reported that when applied intravenously at a dose of 4 mg/kg, capromorelin elicits contractions in the colon of spinal cord-injured rats resulting in spontaneous defecations. Though, the safety profile, tolerability and pharmacokinetic properties of capromorelin was assessed in spinal cord-injured patients with constipation, 49 the currently available data is not detailed enough to support a possible clinical application of capromorelin in the management of constipation. There are no ongoing studies registered in ClinicalTrials.gov, suggesting that its development may no longer being pursued.
EX-1314
Oral administration of the small-molecule EX-1314 (Elixir) at a dose of 300 mg/kg significantly enhanced small intestinal transit in mice, when compared to vehicle-treated controls. 50 The administration of EX-1314 in fed animals resulted in a 2-fold greater fecal output compared to the control group. In contrast, in fasted animals EX-1314 did not show significant differences in fecal pellet outputs. Thus a stimulation of food intake by the synthetic GRLN-R agonist may be needed to facilitate the prokinetic effects of GRLN-R agonists. None of the groups showed signs of diarrhea or other side effects. GRLN-R has prokinetic effects on morphine-induced hypo- motility. EX-1314 reversed the action of morphine and restored the small GI transit in mice to levels observed for controls.
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CP464709
CP46709 is centrally penetrant following subcutaneous or intravenous application and improves colonic motility and defecation patterns in rats. 33, 52 When injected subcutaneously at a dose of 5 or 10 mg/kg, CP464709 caused a substantial stimulation of defecation in the first hour following administration, which represented fourfold increased defecation rates compared to vehicle-treated animals. This effect diminished at greater doses (> 20 mg/kg) suggesting a possible dose-dependent desensitization of receptors. 33, 52 Consistently, rats injected with CP46470 intravenously demonstrated strong propulsive contractions in the colorectum, without changing the baseline motility of the colon. It is thus possible that the GRLN-R agonist activates the defecation center of the L6-S2 lumbo-sacral region of the spinal cord, stimulating autonomic nerve input and thus promoting colorectal motility, without direct effects on colonic smooth muscle cells. 33, 52 This effect was observed in conscious as well as in anesthetized rats, and was manifested by a substantial stimulation of defecation without affecting small intestinal motility.
GSK894281
GSK894281 is another small-molecule that when administered orally to rats enhanced the fecal output nearly four times, compared to controls. 46 The pharmacokinetic evaluation of GSK894281
showed high potency towards GRLN-Rs, with a half-life up to 5.5 hours, and a bioavailability of 75% following oral administration. 46 The peak of fecal expulsion was observed during the first 30 minutes after GSK894281 administration (10 mg/kg) suggesting a very fast onset of action. There is no loss of action since even after chronic administration for 8 consecutive days (daily dose of 10 mg/ kg), GSK894281 maintained a powerful prokinetic effect. The fecal output was approximately 16% greater until the 6th control day after the treatment, compared with the days before the study. A dosedependent increase in fecal output was observed at all time points. It has to be noted that during the period of 8 days rats gained 25% body weight, an observation that mimics the known effects of ghrelin. After discontinuation of GRLN-R agonist, the weight returned to original values. Similarly to other GRLN-Rs agonists, the effects of GSK894281 were probably induced by stimulating receptors in the lumbo-sacral spinal cord.
Ipamorelin
Limited data is available on possible effects of ipamorelin in constipation-related disorders; however, there are in vivo studies and clinical trials assessing its capabilities in the treatment of POI.
Repetitive intravenous administration of ipamorelin (0.1 mg/kg or 1 mg/kg) accelerated colonic transit by shortening the time to the first bowel movement and significantly increased food intake and body weight in a rat model of POI. Single infusions of ipamorelin showed an increase in fecal pellet output. 53 Recently, a multicenter double-blinded, placebo-controlled trial evaluated the safety of ipamorelin on patients with POI following abdominal surgery (ClinicalTrial.gov Identifier: NCT1280344). The treatment with ipamorelin was well tolerated but there were no significant differences in measurable motility parameter between placebo and treated groups. The most common treatment-associated adverse events were consistent with patients having undergone recent bowel surgery ie, nausea, vomiting, and dyspepsia, and may therefore not be associated with ipamorelin. However, the time to recovery of GI function was shorter in ipamorelin-treated group than in placebo. Helsinn Therapeutics, Inc is currently developing ipamorelin in a Phase 2b clinical trial for the future treatment of postoperative bowel dysmotility (ClinicalTrial.gov Identifier: NCT00672074).
Limitations and Directions for Future Research of Ghrelin Receptor Agonist
The majority of studies mentioned in this paper support the notion that the small-molecule ghrelin and GRLN-R agonists may offer a well-integrated therapeutic option for the management of various hypomotility-related disorders, such as CC and POI (Table 2) .
Several consistent results from both animal studies and clinical trials, provide strong evidence for powerful and sustainable effects of RM-131 in improving bowel function and increasing intestinal transit, without causing severe side effects. However, despite holding a great promise, further studies are still needed to fully establish the chronic effects of RM-131 on colonic motility.
As shown by the studies described herein, the effect of GRLN-R agonists on lower GI transit was assessed mainly acutely in vitro and in vivo in the colon. Although most of the investigations followed well-designed protocols, and the results indicated pro-stimulatory actions of each agent on the intestines, none of available studies assessed the effects of a real long-term treatment. Importantly, we should keep in mind that the tested agonists usually desensitize very easily, and thus may not sustain long enough to produce a desirable effect in a chronic mode of application. In line, as mentioned before some GRLN-R agonists prompt colonic motility only after being administered intravenously or subcutaneously. If this beneficial effect of GRLN-R agonists may be maintained also after oral administration, these compounds may be useful in the future management of constipation or to ease cleansing the bowel before colonoscopy. At present, only GSK894281, given orally to rats, have elicited such effects. Presently, GSK894281 is the most promising compound that should be considered for further evaluation in clinical trials, especially being one of the very few that can cross the blood-brain barrier.
While improving the pharmacokinetic properties, it is advisable to consider not only the bioavailability of agents, but also the other effects of ghrelin and GRLN-Rs agonists on appetite, food intake and body weight, since these effects may limit the clinical long term usefulness. For example, EX-1314, which is currently under evaluation in preclinical in vivo studies, and also relamorelin and ipamorelin which have recently completed Phase 2 clinical trials, were associated with stimulation of GRLN-Rs in the appetite centers of the brain and increased appetite, thus their long-lasting use may be limited, especially when patient experience other comorbidities such as metabolic syndrome or type II diabetes. These aspects urgently need further attention, especially in the presently ongoing clinical trials.
In summary, considering the improvement in defecation patterns in animals and humans following administrations of GRLN-R agonists, these agents may herald a new class of anti-constipation drugs. Additional clinical trials are necessary to further characterize and develop the promising clinical effects. 
